Findit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 22, 2021 at 08:58 pm
Share
Findit, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.037619 million compared to USD 0.107239 million a year ago. Net loss was USD 0.031934 million compared to USD 0.19986 million a year ago.
For the nine months, revenue was USD 0.186734 million compared to USD 0.282874 million a year ago. Net loss was USD 0.038741 million compared to USD 0.245311 million a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.